MARKET WIREYahoo Finance • 6h ago
Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst ConferenceYahoo Finance report covering Spruce Biosciences Inc. (SPRB) market action, institutional positioning, and fundamental catalysts.
Why SPRB Stock slipped -0.92% Today — RQD Quant Desk Flash
$46.39 -0.92% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $46.23
Spruce Biosciences Inc. (SPRB) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • SELL / AVOID
Cap $134.6M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on SPRB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is SPRB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Spruce Biosciences Inc. (NASDAQ: SPRB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $46.39 (-0.92% 1D, market cap $134.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SPRB ranks #476 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does SPRB compare to OGI and CATX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SPRB carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OGI (Organigram Global Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC —, cap $135.4M) and CATX (Perspective Therapeutics Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $133.6M). Among the 5-stock peer group, SPRB leads on earnings multiple (N/A) while SPRB leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for SPRB?
▼
Per SPRB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001683553), Spruce Biosciences Inc. generated $0 in revenue (-100.0% YoY), -$39.0M in net income, and -$33.3M in free cash flow against $53.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $46.22 (-0.36%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk C-
Each axis scored 0–20
12M PRICE TARGET CONE-7.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SPRB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (42/100 Composite)
🔍 WHY SPRB SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+14/20 pts (33% of score)
FRED Regime × Technicals: 9% of 52W Range • RSI-14 at 50 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$42.87-5.8% Next Q
34
Q2 (-2Q)Grade E$40.40+8.9% Next Q
37
Q3 (-1Q)Grade E$43.99+5.5% Next Q
39
CurrentGrade D-$46.39-7% Hist 90D α
42
Trajectory: E (34) → D- (42)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a SPRB Turnaround Squeeze
While SPRB currently carries a cautious 42/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($49.89) and Max Pain ($48.71) forces dealer call-delta covering toward $135.45.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $SPRB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SPRB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why SPRB Stock slipped -0.92% Today — RQD Quant Desk Flash
Spruce Biosciences Inc. (SPRB) slipped -0.92% to $46.39, trading at 9% of its 52-week range ($38.06 – $129). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 9% of its 52-week range ($38.06 – $129) with RSI-14 at 50 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $46.39 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live SPRB Headlines & Catalysts
MARKET WIREInvesting.com • 9h ago
B.Riley reiterates Buy on Spruce Biosciences stock, $160 targetInvesting.com report covering Spruce Biosciences Inc. (SPRB) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 12h ago
Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual MeetingYahoo Finance report covering Spruce Biosciences Inc. (SPRB) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 15h ago
Spruce Biosciences (SPRB) Rallies 3.87% to $41.97 as Shares Press Toward Upper Range - Safe Entry Stockshttps://www.siam.in/ report covering Spruce Biosciences Inc. (SPRB) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 18h ago
Spruce Biosciences, Inc. (SPRB) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Spruce Biosciences Inc. (SPRB) market action, institutional positioning, and fundamental catalysts.
RISK WATCHhttps://www.dars.gov.et/ • 1d ago
Spruce Biosciences Q2 2026 Earnings: Wider-Than-Expected Loss Pressures Shares - Upward Estimate Revisionhttps://www.dars.gov.et/ report covering Spruce Biosciences Inc. (SPRB) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SPRB)
- ✓Walkthrough of SPRB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
SPRB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -21.86%📐 HORIZONTAL RANGE
2026-11-02O $46.65H $46.99L $45.48C $46.39VOL 21.0K
RES: $67.08SUP: $37.52SMA50: $49.89SMA200: $55.63
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
SPRB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on SPRB today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for SPRB. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SPRB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SPRB)
Health Care Rank #476 of 1016
⚔️ OGI vs SPRB Full Matrix →
1. Head-to-Head Health Care Peer Comparison (SPRB vs. OGI, CATX, KZIA, HURA)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Spruce Biosciences Inc. (SPRB) ranks #476 by composite RQD confidence (42/100, grade D-) and #624 by equity capitalization ($134.6M). Within this direct 5-issuer industry benchmark cohort, SPRB leads on earnings valuation at N/A trailing P/E, while SPRB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. OGI currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with SPRB at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SPRB
ACTIVE
Spruce Biosciences Inc. | D- | 42/100 | — | — | -35.0% | -0.92% | $134.6M | Benchmark Subject |
| OGI Organigram Global Inc. | C | 62/100 | — | — | — | -2.85% | $135.4M | /ogi-vs-sprb → |
| CATX Perspective Therapeutics Inc. | D- | 37/100 | — | — | -35.0% | -1.71% | $133.6M | /catx-vs-sprb → |
| KZIA Kazia Therapeutics Limited | C- | 61/100 | — | — | — | -2.52% | $135.6M | /kzia-vs-sprb → |
| HURA TuHURA Biosciences Inc. | D- | 40/100 | — | — | -35.0% | -6.31% | $131.3M | /hura-vs-sprb → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001683553In its most recent audited fiscal period (FY2025, filed 2025-12-31), Spruce Biosciences Inc. (SPRB) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $4.9M , and -100.0% cumulative change since FY2023) , GAAP net income of -$39.0M, operating cash flow of -$33.3M, and free cash flow of -$33.3M (+40.4% YoY). On the balance sheet, SPRB closed FY2025 with $53.0M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$39.0M | -$33.3M | -$33.3M | $53.0M | $0 |
| FY2024 (FY) | 2024-12-31 | $4.9M | -$53.0M | -$56.0M | -$56.0M | $45.2M | $124.0K |
| FY2023 (FY) | 2023-12-31 | $10.1M | -$47.9M | -$33.3M | -$33.3M | — | — |
3. SPRB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs SPRB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Spruce Biosciences Inc. (NASDAQ: SPRB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $46.39 (-0.92% 1D, market cap $134.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SPRB ranks #476 in composite RQD confidence.
How does SPRB compare to OGI and CATX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SPRB carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OGI (Organigram Global Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC —, cap $135.4M) and CATX (Perspective Therapeutics Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $133.6M). Among the 5-stock peer group, SPRB leads on earnings multiple (N/A) while SPRB leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for SPRB?
Per SPRB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001683553), Spruce Biosciences Inc. generated $0 in revenue (-100.0% YoY), -$39.0M in net income, and -$33.3M in free cash flow against $53.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is SPRB trading relative to its 50-day, 200-day, and 52-week technical levels?
SPRB last traded at $46.39 (-0.92% on volume of 65,972 shares), positioning the stock -7.02% below its 50-day simple moving average ($49.89) and -16.61% below its 200-day simple moving average ($55.63). Across its 52-week range of $38.06 to $129.00, SPRB sits at the 9.2% percentile with a 14-day RSI of 50.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($40.59 to $52.19).
SPRB Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is SPRB stock moving today?
Why SPRB Stock slipped -0.92% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 42/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
SPRB — Spruce Biosciences Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:43:00Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, SPRB scores 42 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars:
- Fundamental Cash Engine (4 / 20): The lowest-scoring pillar, reflecting ROIC of -35% and an FCF yield of -24.77%. For a prospective investor, this indicates the business is currently consuming cash rather than generating it, so any valuation rests on future outcomes not yet visible in reported cash flows.
- Whale 13F Flow (9 / 20): Institutional accumulation and options positioning are scored below midpoint. Holder-level detail is not available in source data, so the score cannot be decomposed further here.
- Insider Conviction (5 / 20): Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow scored weakly. Investors should treat this as a limited signal of management or insider confidence.
- Macro Regime Fit (14 / 20): With beta of 1.0 and sector sensitivity, the stock's market sensitivity is neutral-to-moderate rather than defensive.
- Forensic Balance Sheet (10 / 20): Altman Z of 0.2, Piotroski F of 4/9, and Debt/Equity of 0.5 point to financial fragility. A low Altman Z in particular signals elevated distress risk under the source's framework.
Implications: Upside drivers would need to come from catalysts that convert pipeline activity into cash generation, which the cash-engine and balance-sheet pillars do not yet demonstrate. Valuation tradeoffs are significant: with negative ROIC and FCF yield, conventional earnings multiples are unavailable, so value depends on forward assumptions the source data does not quantify. This is an educational read of the rating, not personalized advice.
Business
Spruce Biosciences Inc. (SPRB) is a NASDAQ-listed company in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry, per the company profile. Per the recent news catalysts, the company is associated with MPS IIIB natural history data, indicating a focus on rare disease research. Customers, product revenue mix, and monetization model are not available in source data.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-36.5M | $-39.0M | N/A | $-33.3M | $48.9M | $0.0M |
| FY 2024 | $4.9M | $-56.2M | $-53.0M | N/A | $-56.0M | $38.8M | $0.1M |
| FY 2023 | $10.1M | $-52.0M | $-47.9M | N/A | $-33.3M | N/A | N/A |
Per the SEC financials, revenue declined from $10.1M (FY 2023) to $4.9M (FY 2024) to $0.0M (FY 2025), while net losses persisted across all three periods. Gross, operating, and net margins are reported as 0% in the market data, and ROIC is -35%. The Altman Z-Score is 0.2 and the Piotroski F-Score is 4/9, both per the Roarable RQD forensic balance sheet pillar. Cash of $48.9M against debt of $0.0M in FY 2025 indicates a net cash position on the reported figures, while the Debt/Equity ratio is cited as 0.5.
Recent Catalysts & News Wire Analysis
Per the recent news catalysts feed:
- Conference participation: Spruce Biosciences to participate in the Craig-Hallum Biotech Catalyst Conference (YELLOW light, market wire).
- Analyst action: B.Riley reiterated a Buy rating with a $160 target (YELLOW light, market wire). This is a single third-party reference; the price target is far above the $46.82 price and the reliability of this figure is not corroborated elsewhere in the source data.
- Clinical data presentation: MPS IIIB natural history data to be presented at the 55th Child Neurology Society Annual Meeting (YELLOW light, market wire).
- Price action: A report describes a 3.87% rally to $41.97 as shares pressed toward the upper range. This headline conflicts with the current price of $46.82 and should be treated with caution given differing timestamps.
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. All catalysts carry a YELLOW light classification.
Open Questions
- What is the company's pipeline status, and what clinical or regulatory milestones define the path to revenue?
- What drove the decline in revenue from $10.1M to $0.0M, and is any collaboration or licensing income expected?
- What is the cash runway given FY 2025 FCF of $-33.3M against cash of $48.9M?
- Who are the major institutional holders, and how has their positioning changed?
- Why do the news headlines cite prices ($41.97) and analyst targets ($160) that differ materially from the current price and the source's data?
SPRB Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Spruce Biosciences Inc. (SPRB) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 6h ago
Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference Yahoo Finance report covering Spruce Biosciences Inc. (SPRB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 9h ago
B.Riley reiterates Buy on Spruce Biosciences stock, $160 target Investing.com report covering Spruce Biosciences Inc. (SPRB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 12h ago
Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting Yahoo Finance report covering Spruce Biosciences Inc. (SPRB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 15h ago
Spruce Biosciences (SPRB) Rallies 3.87% to $41.97 as Shares Press Toward Upper Range - Safe Entry Stocks https://www.siam.in/ report covering Spruce Biosciences Inc. (SPRB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 18h ago
Spruce Biosciences, Inc. (SPRB) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Spruce Biosciences Inc. (SPRB) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago
Spruce Biosciences Q2 2026 Earnings: Wider-Than-Expected Loss Pressures Shares - Upward Estimate Revision https://www.dars.gov.et/ report covering Spruce Biosciences Inc. (SPRB) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
SPRB Bull vs. Bear Conversation Board — What's Your Call at $46.39?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SPRB 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $41.20 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is SPRB (D- • RQD 42/100) a Buy at $46.82?
Welcome to the SPRB (Spruce Biosciences Inc.) Roar Pit. Current RQD Composite is 42/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $36.99 (-21.0%)
Spot @ $46.82 Pump the brakes on SPRB — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on SPRB, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Spruce Biosciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
QU QuantViper Verified K Arena Trader 🐂 BULLISH
🎯 Target: $53.37 (+14.0%)
Spot @ $46.82 SPRB cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on SPRB, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $46.82 (52-wk range $39.93 - $50.23), any beat on forward guidance forces shorts and underweight funds to chase.